Cargando…
Risk Assessment of Transgender People: Development of Rodent Models Mimicking Gender-Affirming Hormone Therapies and Identification of Sex-Dimorphic Liver Genes as Novel Biomarkers of Sex Transition
Transgender (TG) describes individuals whose gender identity differs from the social norms. TG people undergoing gender-affirming hormone therapy (HT) may be considered a sub-group of the population susceptible to environmental contaminants for their targets and modes of action. The aim of this stud...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913858/ https://www.ncbi.nlm.nih.gov/pubmed/36766819 http://dx.doi.org/10.3390/cells12030474 |
_version_ | 1784885529842548736 |
---|---|
author | Tassinari, Roberta Tammaro, Alessia Lori, Gabriele Tait, Sabrina Martinelli, Andrea Cancemi, Luigia Frassanito, Paolo Maranghi, Francesca |
author_facet | Tassinari, Roberta Tammaro, Alessia Lori, Gabriele Tait, Sabrina Martinelli, Andrea Cancemi, Luigia Frassanito, Paolo Maranghi, Francesca |
author_sort | Tassinari, Roberta |
collection | PubMed |
description | Transgender (TG) describes individuals whose gender identity differs from the social norms. TG people undergoing gender-affirming hormone therapy (HT) may be considered a sub-group of the population susceptible to environmental contaminants for their targets and modes of action. The aim of this study is to set appropriate HT doses and identify specific biomarkers to implement TG animal models. Four adult rats/group/sex were subcutaneously exposed to three doses of HT (plus control) selected starting from available data. The demasculinizing-feminizing models (dMF) were β-estradiol plus cyproterone acetate, at 0.09 + 0.33, 0.09 + 0.93 and 0.18 + 0.33 mg, respectively, five times/week. The defeminizing-masculinizing models (dFM) were testosterone (T) at 0.45, 0.95 and 2.05 mg, two times/week. Clitoral gain and sperm count, histopathological analysis of reproductive organs and liver, hormone serum levels and gene expression of sex-dimorphic CYP450 were evaluated. In the dMF model, the selected doses—leading to T serum levels at the range of the corresponding cisgender—induced strong general toxicity and cannot be used in long-term studies. In the dFM model, 0.45 mg of T represents the correct dose. In addition, the endpoints selected are considered suitable and reliable to implement the animal model. The sex-specific CYP expression is a suitable biomarker to set proper (de)masculinizing/(de)feminizing HT and to implement TG animal models. |
format | Online Article Text |
id | pubmed-9913858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99138582023-02-11 Risk Assessment of Transgender People: Development of Rodent Models Mimicking Gender-Affirming Hormone Therapies and Identification of Sex-Dimorphic Liver Genes as Novel Biomarkers of Sex Transition Tassinari, Roberta Tammaro, Alessia Lori, Gabriele Tait, Sabrina Martinelli, Andrea Cancemi, Luigia Frassanito, Paolo Maranghi, Francesca Cells Article Transgender (TG) describes individuals whose gender identity differs from the social norms. TG people undergoing gender-affirming hormone therapy (HT) may be considered a sub-group of the population susceptible to environmental contaminants for their targets and modes of action. The aim of this study is to set appropriate HT doses and identify specific biomarkers to implement TG animal models. Four adult rats/group/sex were subcutaneously exposed to three doses of HT (plus control) selected starting from available data. The demasculinizing-feminizing models (dMF) were β-estradiol plus cyproterone acetate, at 0.09 + 0.33, 0.09 + 0.93 and 0.18 + 0.33 mg, respectively, five times/week. The defeminizing-masculinizing models (dFM) were testosterone (T) at 0.45, 0.95 and 2.05 mg, two times/week. Clitoral gain and sperm count, histopathological analysis of reproductive organs and liver, hormone serum levels and gene expression of sex-dimorphic CYP450 were evaluated. In the dMF model, the selected doses—leading to T serum levels at the range of the corresponding cisgender—induced strong general toxicity and cannot be used in long-term studies. In the dFM model, 0.45 mg of T represents the correct dose. In addition, the endpoints selected are considered suitable and reliable to implement the animal model. The sex-specific CYP expression is a suitable biomarker to set proper (de)masculinizing/(de)feminizing HT and to implement TG animal models. MDPI 2023-02-01 /pmc/articles/PMC9913858/ /pubmed/36766819 http://dx.doi.org/10.3390/cells12030474 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tassinari, Roberta Tammaro, Alessia Lori, Gabriele Tait, Sabrina Martinelli, Andrea Cancemi, Luigia Frassanito, Paolo Maranghi, Francesca Risk Assessment of Transgender People: Development of Rodent Models Mimicking Gender-Affirming Hormone Therapies and Identification of Sex-Dimorphic Liver Genes as Novel Biomarkers of Sex Transition |
title | Risk Assessment of Transgender People: Development of Rodent Models Mimicking Gender-Affirming Hormone Therapies and Identification of Sex-Dimorphic Liver Genes as Novel Biomarkers of Sex Transition |
title_full | Risk Assessment of Transgender People: Development of Rodent Models Mimicking Gender-Affirming Hormone Therapies and Identification of Sex-Dimorphic Liver Genes as Novel Biomarkers of Sex Transition |
title_fullStr | Risk Assessment of Transgender People: Development of Rodent Models Mimicking Gender-Affirming Hormone Therapies and Identification of Sex-Dimorphic Liver Genes as Novel Biomarkers of Sex Transition |
title_full_unstemmed | Risk Assessment of Transgender People: Development of Rodent Models Mimicking Gender-Affirming Hormone Therapies and Identification of Sex-Dimorphic Liver Genes as Novel Biomarkers of Sex Transition |
title_short | Risk Assessment of Transgender People: Development of Rodent Models Mimicking Gender-Affirming Hormone Therapies and Identification of Sex-Dimorphic Liver Genes as Novel Biomarkers of Sex Transition |
title_sort | risk assessment of transgender people: development of rodent models mimicking gender-affirming hormone therapies and identification of sex-dimorphic liver genes as novel biomarkers of sex transition |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913858/ https://www.ncbi.nlm.nih.gov/pubmed/36766819 http://dx.doi.org/10.3390/cells12030474 |
work_keys_str_mv | AT tassinariroberta riskassessmentoftransgenderpeopledevelopmentofrodentmodelsmimickinggenderaffirminghormonetherapiesandidentificationofsexdimorphiclivergenesasnovelbiomarkersofsextransition AT tammaroalessia riskassessmentoftransgenderpeopledevelopmentofrodentmodelsmimickinggenderaffirminghormonetherapiesandidentificationofsexdimorphiclivergenesasnovelbiomarkersofsextransition AT lorigabriele riskassessmentoftransgenderpeopledevelopmentofrodentmodelsmimickinggenderaffirminghormonetherapiesandidentificationofsexdimorphiclivergenesasnovelbiomarkersofsextransition AT taitsabrina riskassessmentoftransgenderpeopledevelopmentofrodentmodelsmimickinggenderaffirminghormonetherapiesandidentificationofsexdimorphiclivergenesasnovelbiomarkersofsextransition AT martinelliandrea riskassessmentoftransgenderpeopledevelopmentofrodentmodelsmimickinggenderaffirminghormonetherapiesandidentificationofsexdimorphiclivergenesasnovelbiomarkersofsextransition AT cancemiluigia riskassessmentoftransgenderpeopledevelopmentofrodentmodelsmimickinggenderaffirminghormonetherapiesandidentificationofsexdimorphiclivergenesasnovelbiomarkersofsextransition AT frassanitopaolo riskassessmentoftransgenderpeopledevelopmentofrodentmodelsmimickinggenderaffirminghormonetherapiesandidentificationofsexdimorphiclivergenesasnovelbiomarkersofsextransition AT maranghifrancesca riskassessmentoftransgenderpeopledevelopmentofrodentmodelsmimickinggenderaffirminghormonetherapiesandidentificationofsexdimorphiclivergenesasnovelbiomarkersofsextransition |